Head and Neck Cancer Clinical Trial
Official title:
CCCWFU 60307 - Pilot Study to Evaluate the Anti-tumor Effect of Erlotnib Administered Befor Surgery in Operable Patients With Squamous Cell Carcinoma of the Head and Neck (HNSCC)
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may
help doctors learn more about changes that occur in DNA and identify biomarkers related to
cancer. It may also help doctors predict how patients will respond to treatment with
erlotinib.
PURPOSE: This clinical trial is studying how well erlotinib works when given before surgery
in treating patients with head and neck cancer that can be removed by surgery.
OBJECTIVES:
Primary
- Identify tissue biomarkers (primarily the level of phosphorylation of individual
C-terminal EGFR tyrosine sites, measured by nano-LC-MS/MS and markers of main downstream
pathways activation such as P-AKT and P-ERK, measured by nano-LC-MS/MS and by more
clinically standardized IHC) that best associate with response to neoadjuvant erlotinib
hydrochloride treatment in patients with resectable squamous cell carcinoma of the head
and neck (HNSCC).
- Determine the best correlations between levels and changes of different individual
biomarkers (e.g., levels of C-terminal EGFR phosphorylation and recruited adaptors and
markers of downstream pathways activation) in order to evaluate the mechanisms of EGFR
pathway activation in HNSCC and mechanisms of EGFR pathway inhibition by erlotinib
hydrochloride in HNSCC tissue.
- Evaluate post-erlotinib hydrochloride up-regulation of different receptors and molecules
such as HER2 and 3, PDGFR, IGFR, mTOR, src, and aurora kinases, for which there are
already specific inhibitors available for clinical studies.
Secondary
- Evaluate the efficacy by overall response, safety, and tolerability of erlotinib
hydrochloride before surgery in these patients.
- Evaluate the role of FDG-PET scan as a predictor of response to erlotinib hydrochloride.
- Evaluate the role of PET/CT in measuring the response to short-term treatment with
erlotinib hydrochloride.
- Evaluate incidence of risk factors for relapse in the surgical pathology specimens.
OUTLINE: Patients are grouped according to smoking status (non-actively smoking [not smoking,
smoking an average of < 10 cigarettes daily, or smoking for < 1 year prior to enrollment] vs
actively smoking [smoking an average of ≥ 10 cigarettes daily and smoking for ≥ 1 year]).
- Non-actively smoking patients: Patients receive oral erlotinib hydrochloride 150 mg once
daily for at least 14 days. At day 15 patients undergo surgical resection of the tumor.
- Actively smoking patients: Patients receive oral erlotinib hydrochloride 300 mg once
daily for at least 14 days. At day 15 patients undergo surgical resection of the tumor.
Patients undergo biopsies at baseline and after completion of study treatment. Tissue samples
are analyzed by nano-liquid chromatography and mass spectrometry (nano-LC-MS/MS) for markers
of activation and inhibition of different EGFR downstream pathways: PKC, c-Cbl, P-Erk, P-
Akt, P-RAF, src, STAT3 and 5, cyclin D1, and D3, p21 and p27, c-fos, E-cadherin, vimentin,
and correlative up-regulated receptors: Her 2, Her 3, Cox-2, IGF, VEGF, PDGFR, or other
kinases such as src and aurora kinases A and B. The results are confirmed by western blot,
protein array, and immunohistochemistry.
After completion of study treatment, patients are followed at 1 month.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |